ResMed (RMD) reported $1.35 billion in revenue for the quarter ended June 2025, representing a year-over- year increase of 10.2%. EPS of $2.55 for the same period compares to $2.08 a year ago. The reported revenue represents a surprise of +1.87% over the Zacks Consensus Estimate of $1.32 billion. With the consensus EPS estimate being $2.46, the EPS surprise was +3.66%. View all Key Company Metrics for ResMed here>>> Shares of ResMed have returned +8.4% over the past month versus the Zacks S&P 500 composite' ...

ResMed (RMD) reported $1.29 billion in revenue for the quarter ended March 2025, representing a year-over- year increase of 7.9%. EPS of $2.37 for the same period compares to $2.13 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $1.28 billion, representing a surprise of +0.53%. The company delivered an EPS surprise of +0.42%, with the consensus EPS estimate being $2.36. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...